Most people who get Paxlovid are adults (and some teens) with mild‑to‑moderate COVID who are at higher risk of getting seriously ill, and who start the medicine within 5 days of symptom onset. Eligibility details differ by country, so local guidelines and a clinician’s judgement decide who actually gets a prescription.

Basic eligibility

In many places (for example, U.S. FDA and similar programs):

  • Age 18+ (or 12+ and at least 40 kg) with confirmed COVID (PCR or antigen, including home tests).
  • Symptoms are mild to moderate, not severe, and started ≤5 days ago.
  • At least one risk factor for severe COVID (such as age over 50, certain medical conditions, or being under‑vaccinated).
  • Not currently hospitalized because of severe/critical COVID when starting treatment.

Common high‑risk groups

Guidelines list broad groups who are more likely to qualify:

  • Older adults (risk increases over 50; much higher over 65–70).
  • People with serious heart, lung, kidney, liver, neurologic, or metabolic disease (for example heart failure, COPD, advanced CKD, diabetes, obesity).
  • People with weakened immune systems (due to cancer treatment, organ transplant, HIV with immune suppression, certain autoimmune conditions, or immunosuppressive drugs).
  • Some countries also prioritize very elderly people (for example ≥85) or those in care homes.

Who usually should not get it

Some people are excluded or need alternatives:

  • Severe kidney problems (eGFR < 30 mL/min) or severe liver disease.
  • People taking medicines that dangerously interact with ritonavir when they cannot be safely paused or adjusted.
  • Those whose COVID is already severe and requires hospital‑level care at the time of starting treatment.

Why it’s restricted

Health systems try to balance benefit and risk:

  • Paxlovid works best at preventing hospitalization and death in higher‑risk outpatients, so they are prioritized.
  • It has many drug–drug interactions, so prescribers must review all current medications.
  • Access rules have evolved as new data and new variants emerged, and in some countries eligibility has been expanded to reach more at‑risk people.

What to do if you’re unsure

  • Check your country’s official COVID treatment or medicines page for “Paxlovid” eligibility criteria.
  • Use online risk‑factor lists (often based on CDC or national guidance) as a rough guide, then confirm with a clinician.
  • If you test positive and think you’re high‑risk, contact a healthcare provider or telehealth service immediately —Paxlovid is time‑sensitive (needs to start within 5 days of symptoms in most guidance).

Information gathered from public forums or data available on the internet and portrayed here.